Anatomy of a Goal: Justin Meram’s Slip-In Winner – Massive Report

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from the previous weeks Columbus Crew SC match.

For match 25 on the 2017 MLS Season, we take a look at Justin Merams 73rd minute finish that put the Crew SC up 2-1, as part of the 3-1 win over the Chicago Fire on Saturday.

Heres a look at the finish from the Columbus winger.

The Black & Gold evened the match with a first half goal by Kekuta Manneh, and looked to break Chicagos unbeaten streak when scoring first. Columbus put out a speedy lineup, looking to catch the Fire in transition or off turnovers, and thats exactly how all three of the Black & Golds goals were scored.

Merams game winner begins off of a Matt Polster turnover at midfield. In possession of the ball, Chicago made multiple passes back and forth across the midfield line before Crew SC winger Cristian Martinez got in the way of Polsters pass, deflecting the ball to midfielder Wil Trapp.

When Trapp receives the ball, he can either carry the ball between Bastian Schweinsteiger and Dax McCarty, play a quick pass back up the field to Martinez, slot a ball into the path of Ola Kamara, a longer pass across the field to Meram, or a quick square pass to Artur.

As Trapp makes his decision, Waylon Francis makes an excellent run right behind the highlighted Schweinsteiger, who nevers notice a wide-open Francis running all the way down the left flank.

Trapp moves the ball to Martinez, who is defended by Polster. With the Chicago right back providing pressure, Martinez dribbles the ball back toward his defensive half.

Martinez makes a quick pass right back to Wil Trapp, who is now aware of Francis run behind Schweinsteiger, who fails to notice the left back.

Your browser does not support HTML5 video.

For some reason, Polster decides to use Martinez as leverage to change direction, pushing the Columbus winger in the throat and earning himself a yellow card after the play ends.

With the ball at his feet and Polster bearing down, Trapp has to quickly get rid of the ball. He can either play a pass over the head of the oblivious-to-Francis Schweinsteiger, play a difficult pass downfield to Kamara or knock a square pass to Artur.

Trapp notices that Schweinsteiger is looking at the ball while Francis runs, unabated, behind him, so the Black & Gold captain plays one of his excellent long passes right into the path of his wingback.

Francis receives Trapps pass and pushes the ball forward. With Polster having lost the ball at midfield and Schweinsteiger having decided to take this play off, Chicago center-back Johan Kappelhof has to slide over to defend Francis.

Kamara runs in the channel between the two Fire center backs and, with Kappelhof sliding over to mark Francis, Joao Meira must slide over to mark Kamara.

With the three other members of the Chicago backline occupied or out of the play, left back Patrick Doody, who was up the field just as the Fire attacked the ball just seconds before, is forced to chase a wide open Meram. There are no other defenders between Meram and the goal.

In control of the ball, Francis and has three options as Kappelhof attempts to close him down. He can continue to carry the ball toward the goal into a better crossing position, play a quick pass, likely on the ground, into the path of Kamara or go long to Meram, who is still outpacing Doody.

Francis decides to continue carrying the ball forward. As he does this, the referee, signals that he has played the Crew SC advantage from Polsters foul on Martinez.

Meanwhile, as Kamara enters the box he is immediately grabbed on the shoulder and slowed down by Meira. Had Kamara gone to the ground he may have won a penalty, but the Columbus striker stays on his feet and the play continues.

Kappelhof finally closes down Francis who must now cross the ball into the box. Francis has Kamara, defended by Meira, and Meram, defended by no one, as options for a cross.

From the side angle, you can see that Kamara is just offside as Francis prepares to cross the ball. Meram, however, is onside and about five feet ahead of Doody.

As Francis makes his cross, Kamara is definitely offside while Meram continues his run.

Francis ball is destined for Meram, who has beaten Doody and has only former teammate Matt Lampson between him and the back of the net.

Your browser does not support HTML5 video.

If you read the title of this article, you know that Meram scores, so lets take a look at his surprisingly difficult finish from two different angles before we look at the still frames.

After Francis spot-on cross, Meram has to decide how to redirect the ball into the net. A left-footed finish will be difficult, and a right-footed slide-in will have to be inch perfect.

Meram decides to use his right foot, and just gets to the ball with the outside of that foot . . .

. . . and puts the Black & Gold ahead for good.

Findings:

Read more:
Anatomy of a Goal: Justin Meram's Slip-In Winner - Massive Report

Grayson’s Anatomy: How did the Sunderland manager rate after Sunday’s win v Norwich? – Roker Report (blog)

Team Selection: Superb

Simon Graysons decision to play the same side that drew at home to Derby last week was no real surprise. The defence grew into the game, the midfield were energetic and creative and the strikeforce were a real handful - all of which had the fans buzzing.

Grayson decided not to stick with his midweek tinkering, instead opting to keep the front two that had looked dangerous last week, and he will have been delighted with his sides response to the trust he placed in them.

Every player in that starting eleven showed grit, determination, aggression, and a desire to win. It was a pleasure to watch, and fans will be excited at the season ahead. People will rightly point to Aiden McGeady and Lewis Grabban as match winners, but Lee Cattermole was once again phenomenal. Tenacious in defence and active in attack, Catts sprayed the ball around for fun yesterday - Grayson has him and his teammates playing some great football.

Verdict: Team selection was consistent and players are buying into Graysons tactics - fantastic to watch.

For so long last season we yearned for a side capable of playing fast, direct football and yesterday Sunderland provided just that.

Norwich had over 70% of the possession, yet struggled to fashion clear cut chances - instead relying on set-pieces to create the vast majority of their opportunities on goal. Graysons men on the other hand were compact and incredibly difficult to break down. Norwich just couldnt find a way through other than for an unfortunate Grabban own goal, and that stubbornness in defence was absolutely superb.

When Sunderland had the ball though, they were efficient with it and put the Norwich defence to the sword. Weve noted before that Graysons side like to mix up their style of play, and yesterday again showed that. The first goal was route one, the second a piece of individual brilliance, and the third a direct goal that came from some neat build up play. Sunderland seem comfortable playing a number of different ways and that can only be a good thing going forward.

Verdict: Grayson has his tactics spot on, and with another couple of additions he will have a squad depth capable of maintaining his style of play across a long, arduous season.

The game was essentially won by the time Grabban completed a peculiar hat-trick, but Grayson waited until the final 15 minutes to make his changes. Youd imagine that was to keep the structure that had worked so well throughout the game intact, and youll find no complaints about that here.

Yesterday was a great win and I dont want to delve too deep into the inner workings of Graysons subs - they came on, steadied the ship and provided fresh legs. Job done.

Verdict: Would like to see some youngsters given more game time going forward, but yesterday was all about the three points - which we duly earned.

Grayson noted immediately just how important the win was for his Sunderland side, and how impressed he was with his players:

This is a tough place to come to and we knew they would be putting us under pressure in their first home game of the season, but I thought the lads stuck to the game plan really well.

That being said, Grayson was also quick to remind fans and players alike that the season is merely in its infancy, and theres a long way to go:

It's a great win and it has been a strongish start for us - but that's all it is, a good start, and no-one is getting carried away.

Graysons steely tone continued on as he provided yet more soundbites to get the fans on board. Looking forward is key if Sunderland are to succeed this season, and Grayson knows that quite clearly:

What has happened here is in the past - it's all about what happens in the future now and what I will say is that I have got a good, hard-working group here - it's a working class city and that's what the people demand.

So a 3-1 win and a brilliant performance, yet Grayson wants more? Class! The man is clearly an ambitious manager, and its exciting to hear him talk about needing to carry on with this good form. For too long the club have been stuck in a short-termist approach to football - Simon Grayson, however, seems the real deal as he builds a squad aiming to finish high.

Verdict: Impressed with the way Grayson is keen to keep his players grounded. Yes the result was brilliant and Im sure hell have told the players just that, but as he mentioned, its still early days. Grayson, however, seems just the man to keep these Lads on the right track. A superb win and performance.

See the article here:
Grayson's Anatomy: How did the Sunderland manager rate after Sunday's win v Norwich? - Roker Report (blog)

Gillette Stadium announces ‘Super Bowl LI: Anatomy of a Comeback’ – Wicked Local Foxborough

FOXBOROUGH Patriots fans visiting the practice fields behind Gillette Stadium to catch a glimpse of the 2017 team at training camp will also have an opportunity to relive the teams most recent championship through the newly renovated Super Bowl Experience exhibit now featuring, Super Bowl LI: Anatomy of a Comeback.

The newly renovated area of the Super Bowl Experience uniquely tells the story of the greatest comeback in Super Bowl history. The Anatomy of a Comeback features eight monitors two 55-inch displays and six 22-inch mosaic, tile-like displays. The hall conducted exclusive interviews with Patriots head coach Bill Belichick, wide receiver Julian Edelman, running back James White, defensive back Devin McCourty and defensive lineman Trey Flowers to give fans firsthand accounts of how the Patriots dramatic overtime victory in Super Bowl LI unfolded.

For information: http://thehallatpatriotplace.com.

Continued here:
Gillette Stadium announces 'Super Bowl LI: Anatomy of a Comeback' - Wicked Local Foxborough

aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology … – GlobeNewswire (press release)

Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical Trial Project ORCA: Leverages a New Immuno-Oncology Antibody Target Based on Physiocrine Biology

SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced operating results for the second quarter ended June 30, 2017.

During the first half of 2017, our team advanced three innovative, first-in-class biologics that harness Physiocrine biology in immunology, said John Mendlein, Ph.D., CEO of aTyr Pharma. For our Resolaris program, we report favorable safety data from two extension studies in patients with rare muscular dystrophies underscoring the potential for improved clinical outcomes over time based on stabilizing or improving muscle function. In addition, we plan to initiate our first-in-human clinical trial for our iMod.Fc program for ILD. Our third program, ORCA targets a novel, proprietary immuno-oncology pathway using antibodies to change levels of Resokine in tumor settings. We believe tumors utilize Resokine to evade immune system responses. Our Resolaris, iMod.Fc and ORCA programs demonstrate the power and leverage arising from our new insights in immunology and novel therapeutic modalities targeting homeostatic pathways.

Resolaris Program First Resokine Therapeutic Candidate Based on a Protein Secreted by Muscle

Safety Extension Study Results (005 and 006) aTyr recently completed two extension studies in patients with limb-girdle muscular dystrophy 2B (LGMD2B), adult facioscapulohumeral muscular dystrophy (FSHD), and early onset FSHD. Per protocol patients received 3.0 mg/kg of Resolaris weekly in these extension studies.

Promising Clinical Results for Resolaris in Early Onset FSHD During the quarter, aTyr announced top-line results from its Phase 1b/2 trial (003) of Resolaris in patients with early onset FSHD. Overall, 63% of patients (5/8) showed an increase from baseline in their MMT score, with a mean change from baseline of +3.8%. Resolaris was generally well-tolerated at doses up to 3.0 mg/kg once weekly in this younger patient population (patients in the trial were between the ages of 16 and 20) with no observed signs of general immunosuppression.

AAN Presentation During the quarter, Dr. John Vissing, M.D., Ph.D., Professor of Neurology, University of Copenhagen, presented a poster titled Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR-C-004) at the American Academy of Neurology (AAN) Annual Meeting on April 25, 2017 in Boston, MA.

Clinical Development Plan Initiation of a randomized placebo-controlled trial with Resolaris is contingent upon the identification of a PD assay and execution of a partnership related to one of our pipeline programs.

iMod.Fc Program First Fc Fusion Based Therapeutic Candidate for Lung Diseases

Clinical Development aTyr Pharma plans to commence a Phase 1 clinical program for the iMod.Fc program later this year. This randomized, double-blind, placebo-controlled study will investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics (PD) of intravenous iMod.Fc in healthy volunteers.

American Thoracic Society (ATS) Presentations During the quarter, aTyr Pharma presented two posters on the iMod.Fc program at the ATS International Conference May 19 - 24, 2017 in Washington, D.C.:

In conjunction with the ATS presentations, aTyr Pharma hosted an educational webinar featuring Dr. Steven D. Nathan, M.D., FCCP, Director of the Advanced Lung Disease Program and Lung Transplant Program at Inova Fairfax Hospital, to provide disease education on interstitial lung diseases that are characterized by an immune component, such as idiopathic pulmonary fibrosis (IPF), sarcoidosis, and chronic hypersensitivity pneumonitis (CHP). The webinar is available on the aTyr Pharma investor website.

Project ORCA First Antibody Antagonist to a Physiocrine Immunology Pathway

New Target in Immuno-Oncology ORCA involves a novel and proprietary target that aTyr believes is active across multiple tumor types.

Timeline aTyr plans to select an antibody as a potential IND candidate in 2017.

Second Quarter 2017 Financial Results

Research and development expenses were $8.4 million and $11.3 million for the quarters ended June 30, 2017 and 2016, respectively. The decrease of $2.9million was due primarily to a $2.2 million decrease related to Resolaris clinical trials costs and $0.6 million decrease related to manufacturing costs incurred in support of Resolaris.

General and administrative expenses were $3.5million and $4.1million for the quarters ended June 30, 2017 and 2016, respectively. The decrease of $0.6 million was due primarily to a $0.4 million reduction in professional fees.

First Half 2017 Financial Results

Research and development expenses were $17.6 million and $23.3 million for the six months ended June 30, 2017 and 2016, respectively. The decrease of $5.7million was due primarily to $4.2 million decrease related to manufacturing costs incurred in support of Resolaris and $2.3 million decrease related to Resolaris clinical trials costs. The decrease was partially offset by an increase of $1.0 million related to research and non-clinical development costs incurred for iMod.Fc.

General and administrative expenses were $7.5 million and $8.2 million for the six months ended June 30, 2017 and 2016, respectively. The decrease of $0.7 million was due primarily to a $0.4 million decrease in professional fees.

Financial Guidance

As ofJune 30, 2017, aTyr had$57.2 millionin cash, cash equivalents and investments and 23.8 million shares of common stock outstanding.

aTyr expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into the third quarter of 2018.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of immunological and physiological pathways. To date, the Company has generated three innovative therapeutic programs based on its knowledge of Physiocrine biology in three different therapeutic areas and three different biologic modalities. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding, the potential and potential therapeutic benefits of Resolaris, iMod.Fc, or potential product candidates from Project ORCA, the ability of the Company to successfully advance its pipeline or product candidates, undertake certain development activities (such as clinical trial enrollment and the conduct of clinical trials) and accomplish certain development goals and the timing of such activities and development goals, the timing of initiation of additional clinical trials, the scope and strength of our intellectual property portfolio, our ability to receive regulatory approvals for, and commercialize, our product candidates and of reporting results from our clinical trials, and our projected cash expenditures reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our Physiocrine-based product candidates, as well as those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2016 and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the original:
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology ... - GlobeNewswire (press release)

Maui High graduate spends summer turning raw data into cancer research – Maui News

Maui High School graduate Phyllis Raquinio stands by her research project on the connection between Type 2 diabetes and cancer survival rates at the University of Hawaii Cancer Center. Raquinio was one of 19 interns selected to conduct research at the center over the summer. Raquinio majors in molecular cell biology and will be a senior at UH-Manoa in the fall. University of Hawaii Cancer Center photo

Instead of enjoying a lazy, carefree vacation, Maui High graduate Phyllis Raquinio was hard at work this summer poring over cancer data, discussing how hula and physical activity can help post-survival cancer patients and learning how advertisements can play a role in the growing consumption of e-cigarettes.

Raquinio was one of 19 students selected and the only Maui graduate to conduct research as an intern at the University of Hawaii Cancer Center.

I did not know a lot about cancer and wanted to learn more about it to have a better idea on how cancer research is conducted, Raquinio said via email Sunday. I was surprised to be accepted in the internship, considering how competitive it was, but I was extremely excited to start working and helping expand my knowledge of cancer.

The UH Cancer Center is one of 69 research institutions designated by the National Cancer Institute. It started an internship program in 2004, said Yvette Amshoff, education and outreach coordinator at the Cancer Center.

While many of (the interns) are interested in careers as doctors, we aim to show the many opportunities in cancer research and how research is important to enforcing new regulations, clinical practices and cancer cures in the health setting, Amshoff explained.

According to the center, interns are chosen from public and private schools from across the state and the nation in a highly competitive process. This year, 19 out of 74 applicants were selected, with an average grade point average of 3.77. Program funding comes from the National Cancer Institute, the Meiji Yasuda Life Insurance Co. and the Friends of the Cancer Center.

Interns work under the guidance of faculty members and learn about new advances in research and technology. At the end of the program, each intern submits a project on a topic of his or her choice. Joe Ramos Jr., deputy director and professor at the center, explained that students can either explore cancer biology, which takes a look at the molecular mechanisms behind cancer, or population sciences in the Pacific.

Students like Ms. Raquinio who go into the population sciences in the Pacific projects are examining how the environment (what we eat, smoke or are otherwise exposed to in Hawaii) and our genes and behaviors interact to affect cancer risk, cancer progression and survival outcomes, Ramos said.

For example, Ms. Raquinio examined how having type 2 diabetes affected survival of patients with breast cancer and colon cancer. This is part of a continuing project on this topic. If we can understand these connections better, we can better prevent people in Hawaii and the Pacific from getting cancer or improve their survival chances.

Born and raised on Maui, Raquinio graduated from Maui High School in 2014. She said a few of her friends interned at the center last summer and encouraged her to apply. While her grandfather and a close instructor suffered from cancer, Raquinio said her interest stemmed mainly from the biology behind cancer. At UH, she majors in molecular cell biology with a minor in English.

Over the summer, Raquinio worked with Dr. Gertraud Maskarinec, analyzing data from a large, multiethnic population study in Hawaii. The study included more than 215,000 participants. Of that group, 5,000 had been diagnosed with colorectal cancer and 7,500 had been diagnosed with breast cancer.

Phyllis was a very dedicated intern, Amshoff said. Learning how to use statistical software to analyze a large data set can be very tricky, but Phyllis caught on quickly, and now her findings are being refined to be submitted to a journal.

Raquinio said the study produced unexpected results but explained that she was still completing her paper and working to better understand the results before reporting them.

As an intern, Raquinio said she learned a lot from interns researching other topics and gained a better understanding of the process for clinical studies and why it takes a long time for treatments to be approved.

This internship has opened my mind to potentially pursuing cancer research, Raquinio said. It has helped me understand more about specific cancers, how biology plays a role, and the processes to conducting research for treating cancer.

Raquinio said she hopes to enroll in medical school after she graduates, with eventual plans to become a doctor.

Ms. Raquinio and the other students bring a fresh perspective and enthusiasm to the projects that makes working with them tremendously rewarding for the mentors, Ramos said. I am consistently impressed that these students come in with very little to no experience working in cancer research and quickly get their bearings and leave with a real appreciation for the kind of disciplined inquiry and experimentation required to make important advances in understanding and treating cancer.

* Colleen Uechi can be reached at cuechi@mauinews.com.

View post:
Maui High graduate spends summer turning raw data into cancer research - Maui News

Change in protein production essential to muscle function – Baylor College of Medicine News (press release)

The researchers discovered that the genetic activity of mouse skeletal muscles is particularly intense during the first two weeks after birth; a number of genes alter the amount of proteins produced, while other genes go through alternative splicing and produce different proteins.

Among the genes going through alternative splicing, those involved in calcium-handling functions predominated. Calcium is very important for skeletal and heart muscle because the influx of calcium into the cell stimulates contraction and other functions.

First author Dr. Amy Brinegar, who was a graduate student in the Cooper lab while she was working on this project and recently graduated from the doctoral program in molecular and cellular biology at Baylor, selected three calcineurin A genes, which are involved in calcium-handling functions, and reversed their natural process of alternative splicing in adult mouse muscles. Then, Dr. George Rodney, associate professor of molecular physiology at Baylor, and a graduate student in his lab, James Loehr, who are co-authors on this paper, determined the effect of switching back alternative splicing on functions of isolated adult mouse skeletal muscle in the lab.

They discovered that muscles in which the adult forms of the calcineurin A genes had been switched back to the newborn forms showed a change in calcium flow and were less strong than muscles that retained the adult forms of calcineurin A.

We showed that just by changing three of about 11,000 genes that are estimated to be expressed in adult mouse muscle, we were able to change physiological parameters of those muscles, said Brinegar. This work supports the growing evidence in favor of a physiological role of alternative splicing.

Importantly, about 50 percent of the genes we discovered to undergo alternative splicing are conserved, meaning that the genes go through the same changes both in mice and humans, which opens the possibility of modeling human muscle disorders in the mouse, Cooper said.

Other contributors top this work include Zheng Xia and Wei Li, both from Baylor.

Financial support was provided by National Institutes of Health grants R01AR045653, R01HL045565, R01AR060733, T32 HL007676, R01HG007538, R01CA193466 and R01AR061370. Further support was provided by the Muscular Dystrophy Association grant RG4205.

Read the original post:
Change in protein production essential to muscle function - Baylor College of Medicine News (press release)

AAU Physiology HOD Proposes To Girlfriend At Student Dinner Night – Information Nigeria

The head of Department of the Physiology Department, Ambrose Alli Unversity, Dr Ernest Nwoke, proposes to his girlfriend at the student dinner night.

It was a night to be remembered as the student and lecturers present were amazed with the expression of love be from the Pragmatic HOD, Dr Ernest Nwoke.

According to reports, Nwoke lost his wife and has found love again in the pretty young lady.

Congratulations to the couple.

Read this article:
AAU Physiology HOD Proposes To Girlfriend At Student Dinner Night - Information Nigeria

She is The First – HuffPost

Stanford University professor Maryam Mirzakhami, who recently came to my attention through her obituary, is the first and only woman to date to win the Fields Medal in Mathematics. She brings to my mind other women who were the first to win prestigious prizes and awards. Some of these firsts have occurred only recently. Match the woman with her accomplishment:

_____ 1. The first African-American to receive the Pulitzer Prize in Poetry.

_____ 2. The first black woman of any nationality to receive the Nobel Prize in Literature.

_____ 3. In 2010, 80 years after the first Oscars were awarded, she became the first woman to win the Academy Award for Best Director.

_____ 4. The first woman to receive the Nobel Prize in Economics.

_____ 5. The first American woman to receive a Nobel Prize in the sciences.

In 1947, when biochemist Gerty Cori received the Nobel Prize in Physiology or Medicine, she became the first American woman to win a Nobel Prize in the sciences and the first woman to receive the Nobel Prize in Physiology or Medicine. Today, what is known as the Cori cycle (named after Gerty and her husband Carl) describes the metabolism of carbohydrates and is important to the understanding of diabetes. Her research on enzymes led to her being the first to demonstrate that a defect in an enzyme could be the cause of a human genetic disease. Cori experienced much discrimination during her career but achieved in spite of that discrimination and received many honors. In addition to being inducted into the National Womens Hall of Fame, features on the Moon and Venus have been named for her.

Author, poet and teacher Gwendolyn Brooks began writing at an early age, encouraged to do so by her mother. Her first poem was published when she was 13 and by 16, she had already published 75 poems. Much of her work reflected her life experiences in the inner city of Chicago. Her first book of poetry was published in 1945. In 1950, when she won the Pulitzer Prize for Poetry, she became the first African-American to receive that honor. Appointed to a position that is now called the Poet Laureate Consultant in Poetry to the Library of Congress, Brooks has also been inducted into the National Womens Hall of Fame.

The first black woman of any nationality to win the Nobel Prize in Literature, Toni Morrisons citation reads who in novels characterized by visionary force and poetic import, gives life to an essential aspect of American reality. Morrison has written novels, plays and operas, many dealing with the black experience in America. Earlier in her career, Morrison worked in the publishing business and ensured that works by black authors were published. Her 1977 book Song of Solomon brought her national attention. Beloved, her most celebrated novel and a bestseller, was published in 1987, received the Pulitzer Prize for fiction and was made into a film starring Oprah Winfrey and Danny Glover. Morrison spent many years on the faculty at Princeton University and has received multiple honorary degrees.

The first woman to receive the Nobel Prize in Economics, Elinor Ostroms citation reads for her analysis of economic governance, especially the commons. She received her Ph.D. in political science, unable to pursue economics as she had been denied admission to trigonometry. During her years at Indiana University and Arizona State University, Ostrom focused on issues related to collective action, trust and cooperative use in the management of common pool resources which include forests, parks, fisheries, grazing land and irrigation systems. Her later work involved human interaction with ecosystems. There is even a law named for her; Ostroms law reads A resource arrangement that works in practice can work in theory. Ostroms many honors in addition to the Nobel Prize include election to the National Academy of Sciences.

In 2010, eighty years after the first Oscars were awarded, Kathryn Bigelow became the first woman to win the Academy Award for Best Director. A director, producer and writer, Bigelow won the award for The Hurt Locker. Originally educated as a painter, Bigelow received her Bachelors in Fine Arts from the San Francisco Art Institute in 1972. Her masters degree in film was earned at Columbia University. Her first full-length feature was released in 1982. Bieglows mainstream films are generally characterized as action films. Her latest film for which she directed and produced, Detroit, is currently playing in theatres. She said There should be more women directing; I think theres just not the awareness that its really possible. It is.

Learn about more she-roes and celebrate amazing women. These women who achieved firsts are among the more than 850 women profiled in the book Her Story: A Timeline of the Women Who Changed America. I am proud to tell womens stories and write women back into history. I stand on their shoulders.

(Answers: 1-B, 2-C, 3-E, 4-D, 5-A)

The Morning Email

Wake up to the day's most important news.

Originally posted here:
She is The First - HuffPost

Please Ignore The Celebrity Hype, Fertility Really Does Decline With Age – HuffPost

Fertility is one hot topic and that means it gets a lot of media coverage. The good news is that theres so much valuable information now widely available - in the news and online - to help couples learn about fertility and the factors that affect their ability to get pregnant. The bad news is that theres a lot of misleading information, too. In fact, its hard to go a single week without hearing about someone famous who just had a baby at 46. While you might want such a medical miracle to be true and commonplace, in fact, pregnancy at this age is very much the exception, not the rule.

The truth is that timing makes a difference and those wanting to get pregnant should pay attention to facts from credible sources when planning for a family. Many people women and men dont fully understand how much their fertility declines with age, and the supposed proliferation of older women giving birth often without disclosing they used eggs from much younger donors may give those who want to start a family a false sense of security. This is true for women over the age of 38 and younger women freezing their eggs while in their 20s for use much later when theyre ready.

Globally, men and women are delaying the birth of their first child. While this is due to a multitude of reasons--from finances to having the right partner--a group of stakeholders in the UK want to make sure decisions made to delay pregnancy come with the understanding of age-related decline in fertility, especially for women over the age of 35.

This major decline in fertility is underscored by data from the UKs Human Fertilization and Embryology Authority (HFEA) which shows the live birth rate using assisted reproductive technology (ART) is 32.3% for women younger than age 35 but decreases to 13.6% for women ages 40-42, and drops to 5% for ages 43-44. By not knowing these major differences due to age, a growing number of couples are finding they have inadvertently missed their reproductive chance.

In fact, the UK stakeholder group believes the media perpetuates misinformation by highlighting individual cases of pregnancy in later years while suggesting assisted reproductive technology (ART), such as in vitro fertilization (IVF) can compensate fully for age-related decline. As a result, they have established the Fertility Education Initiative to develop tools and information for children, adults, teachers, parents and healthcare professionals dedicated to improving knowledge of fertility and reproductive health.

What can you do to be aware and well-informed, so that your decision making on when to try and get pregnant is based on fact, not fiction? You can sort the good information from the bad a few ways:

Good information is based on research and clinical evidence. Your doctor can tell you the latest facts about what affects fertility and discuss how your unique situation age, health status, medical history, genetics, and lifestyle (and that of your partner) affects your individual chance of becoming and staying pregnant.

There are professional and consumer groups that have as their mission or focus educating consumers with reliable and easy to understand information. Three of the best include the professional societies of fertility specialists: the American Society for Reproductive Medicine (ASRM), the Society for Advanced Reproductive Technology (SART) and the consumer advocacy group RESOLVE: The National Infertility Association The information on their websites is evidence-based, current and updated when we learn more about what impacts fertility through credible research and clinical outcomes.

A number of media outlets are also trying to do their part for greater awareness of the factors that affect fertility, including age. It makes a difference if coverage includes information from fertility specialists and doesnt simply offer a few patient anecdotes. Bride magazine recently published several fact-based articles which include interviews with fertility specialists and emphasize the impact of age on a womans fertility.

For example, in one article, Dr. Mazen Abdallah, a reproductive endocrinology and infertility specialist with McGovern Medical School at UTHealth, offers age-related advice on seeking treatment, suggesting that if a woman younger than 35 tries for a year to get pregnant without success she should seek treatment. However, if a woman is over the age of 35, she should seek a workup and treatment after 6 months of trying unsuccessfully. Women over the age of 40 should see a fertility specialist if theyre not pregnant within 3 months of trying.

If youre thinking about starting a family, get your information about fertility from the right sources including your doctor. Start with filing those celebrity pregnancy stories under entertainment. Know that everyones fertility declines with age. That way, you can start planning for a baby when the time is right and most realistic.

See the article here:
Please Ignore The Celebrity Hype, Fertility Really Does Decline With Age - HuffPost

Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes – Nasdaq

On Aug 11, we issued an updated research report on Salt Lake City, UT-based molecular diagnostics provider, Myriad Genetics, Inc. MYGN . The company currently carries a Zacks Rank #3 (Hold).

For the past three months, Myriad has been trading above the broader industry . The company has rallied 24.7%, compared with the industry's 3.7% gain.

Myriad ended fiscal 2017 on a solid note, with its fourth-quarter numbers exceeding the Zacks Consensus Estimate. The company particularly observed strong growth in EndoPredict and GeneSight testing revenues. Also, Myriad witnessed a third consecutive quarter of rise in hereditary cancer volumes. Also, it received provincial reimbursement in Quebec for EndoPredict.

Notably, at the European League Against Rheumatism (EULAR) meeting held in June in Spain, Crescendo Bioscience, a wholly-owned subsidiary of Myriad, released new data from a meta-analysis of clinical studies. The data has demonstrated the Vectra DA test's ability to predict a joint damage.

The same month, the company announced that its BRACAnalysis CDxcompanion diagnostic test has successfully identified BRCA -mutated patients with HER2- metastatic breast cancer in the OlympiAD trial, who have responded to treatment with olaparib better than standard chemotherapy.

Myriad's collaborations with AstraZeneca and BeiGene for development of companion diagnostics also raise optimism. Moreover, Myriad continues to make progress with its kit-based versions of Prolaris and myPath Melanoma in the international market and expects to file for CE Mark for Prolaris by 2018.

Moreover, the company has introduced its 'Elevate 2020' program that targets to achieve $50 million of incremental operating income by fiscal 2020. Per management, the company has selected the projects that are anticipated to deliver $17 million of operating income in fiscal 2018 and another $24 million in fiscal 2019.

On the flip side, unfavorable currency translation continues to be a major dampener for the stock. Management fears that further strengthening of the dollar against foreign currencies will lead to deteriorating operating results.

Intensifying competition as well as the possibility that Myriad's new test might not generate meaningful profits to outweigh the costs associated with its development continues to raise concern.

Zacks Rank and Key Picks

Some better-ranked medical stocks are Edwards Lifesciences Corp. EW , Steris Plc STE and Align Technology, Inc. ALGN . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Steris carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Edwards Lifesciences has a positive earnings surprise of 10.75% over the trailing four quarters. The stock has gained around 0.9% over the last three months.

Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 25.4% over the last three months.

Steris has a positive earnings surprise of 0.78% over two of the trailing four quarters. The stock has gained 13.1% over the last three months.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Align Technology, Inc. (ALGN): Free Stock Analysis Report

STERIS PLC (STE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Excerpt from:
Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes - Nasdaq